menu
    • menu

    Company profile for Biomea Fusion

    NEW Drugs in Dev: 4
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs including greater target selectivity, lower drug exposure and the a...
    We are a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biomea FusionUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Chamberlain Building 726 Main St.Redwood City, CA 94063
    Telephone
    Telephone
    (650) 980-9099
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://biomeafusion.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PCHi

    PCHi

    Not Confirmed

    envelop Contact Supplier

    PCHi

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biomea Fusion Presents COVALENT-111 Phase 2 T2D Data at ATTD 2026
    Biomea Fusion Presents COVALENT-111 Phase 2 T2D Data at ATTD 2026

    14 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/14/3255846/0/en/Biomea-Fusion-Presents-Phase-II-COVALENT-111-Data-in-Type-2-Diabetes-at-the-19th-International-Conference-on-Advanced-Technologies-Treatments-for-Diabetes-2026.html

    GLOBENEWSWIRE
    14 Mar 2026
    Share Share
    Biomea Fusion To Participate At Upcoming Investor Conferences
    Biomea Fusion To Participate At Upcoming Investor Conferences

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3240949/0/en/Biomea-Fusion-to-Participate-at-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Biomea Fusion Focuses On Key Icovamenib And BMF-650 Milestones
    Biomea Fusion Focuses On Key Icovamenib And BMF-650 Milestones

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216849/0/en/Biomea-Fusion-Enters-2026-Focused-on-Executing-Key-Icovamenib-and-BMF-650-Milestones.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Biomea Fusion To Present At J.P. Morgan Healthcare Conference
    Biomea Fusion To Present At J.P. Morgan Healthcare Conference

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206863/0/en/Biomea-Fusion-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Biomea Fusion Presents Menin And Icovamenib Data At WCIRDC 2025
    Biomea Fusion Presents Menin And Icovamenib Data At WCIRDC 2025

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202858/0/en/Biomea-Fusion-Announces-KOL-Presentation-and-Interview-on-Menin-and-Icovamenib-at-WCIRDC-2025.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Biomea Fusion Unveils COVALENT-111 Study Results At WCIRDC
    Biomea Fusion Unveils COVALENT-111 Study Results At WCIRDC

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200588/0/en/Biomea-Fusion-Presents-COVALENT-111-Study-Results-at-the-23rd-World-Congress-on-Insulin-Resistance-Diabetes-Cardiovascular-Disease-WCIRDC.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search